Korean J Fam Pract. 2018; 8(2): 164-168  https://doi.org/10.21215/kjfp.2018.8.2.164
Effect of Obesity Index on Prostatic Hyperplasia
Byung-Soo Kang, Soo-jin Ma, Hyung-Ho Choi*
Department of Family Medicine, Chosun University College of Medicine, Gwangju, Korea
Hyung-Ho Choi
Tel: +82-62-220-3608, Fax: +82-62-223-0031
E-mail: hhchoi@chosun.ac.kr
ORCID: https://orcid.org/0000-0003-4463-6441
Received: March 9, 2017; Revised: October 11, 2017; Accepted: October 19, 2017; Published online: April 20, 2018.
© The Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Obesity-related metabolic disease can influence prostatic hyperplasia. We studied the relationship between obesity and prostatic hyperplasia.
Methods: We recruited 155 men who underwent transrectal ultrasonography during a health checkup. The patients were divided into 3 subgroups according to body mass index (BMI) (normal, 18.5–22.9 kg/m2; overweight, 23.0–24.9 kg/m2; and obese, ≥25.0 kg/m2) and into 2 subgroups according to waist circumference (normal, <90 cm; central obesity, ≥90 cm). We compared the correlation among prostate volume, BMI, and waist circumference, and analyzed their association with prostatic hyperplasia.
Results: No significant differences in age were found across the normal (45.9±9.0 years), overweight (51.5±7.6 years), and obese groups (50.6±9.4 years), and between the normal waist (48.1±9.8 years) and central obese groups (50.3±9.2 years). A significant difference in prostate volume was found between the normal and obese groups (P=0.04), and between the normal waist and central obese groups (P=0.01). High BMI (adjusted odds ratio [OR], 2.75; P=0.042; 95% confidence interval [CI], 1.04–7.24) and central obesity (adjusted OR, 2.51; P=0.015; 95% CI, 1.19–5.25) were independent factors associated with prostatic hyperplasia.
Conclusion: We conclude that both obesity and central obesity influence prostate volume. We also conclude that obesity and central obesity are independent factors associated with prostatic hyperplasia. The correlation between obesity and prostatic hyperplasia should be investigated, including additional clinical symptoms and risk of prostatic hyperplasia.
Keywords: Obesity; Body Mass Index; Waist Circumference; Prostatic Hyperplasia
References
  1. National Heart, Lung, and Blood Institute in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, (MD): National Heart, Lung, and Blood Institute; 1998.
  2. Kim DM, Ahn CW, Nam SY. Prevalence of obesity in Korea. Obes Rev 2005;6: 117-21.
    Pubmed CrossRef
  3. Ekman P. BPH epidemiology and risk factors. Prostate Suppl 1989; 2: 23-31.
    Pubmed CrossRef
  4. Park YH, Chung MK. The prevalence of clinical benign prostatic hyperplasia and lower urinary tract symptoms in South-East Korea: a communitybased study. J Pusan Natl Univ Hosp 2001; 9: 141-57.
  5. Lee MW, Lee KS. The prevalence of benign prostatic hyperplasiain self-referral populations over aged 50. Korean J Urol 1996; 37: 263-7.
  6. Soygür T, Küpeli B, Aydos K, Küpeli S, Arikan N, Müftüoğlu YZ. Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. Int Urol Nephrol 1996; 28: 55-9.
    Pubmed CrossRef
  7. Daniell HW. Larger prostatic adenomas in obese men with no associated increase in obstructive uropathy. J Urol 1993; 149: 315-7.
    CrossRef
  8. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994; 140:989-1002.
    Pubmed CrossRef
  9. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 47: 193202.
    CrossRef
  10. Troisi RJ, Weiss ST, Parker DR, Sparrow D, Young JB, Landsberg L. Relation of obesity and diet to sympathetic nervous system activity. Hypertension 1991; 17: 669-77.
    Pubmed CrossRef
  11. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151-8.
    Pubmed CrossRef
  12. Pollack HM. Imaging of the prostate gland. Eur Urol 1991; 20 Suppl 1: 50-8.
    Pubmed CrossRef
  13. Collins GN, Raab GM, Hehir M, King B, Garraway WM. Reproducibility and observer variability of transrectal ultrasound measurements of prostatic volume. Ultrasound Med Biol 1995; 21: 1101-5.
    CrossRef
  14. Hastak SM, Gammelgaard J, Holm HH. Transrectal ultrasonic volume determination of the prostate--a preoperative and postoperative study. J Urol 1982; 127: 1115-8.
    CrossRef
  15. Jones DR, Roberts EE, Griffiths GJ, Parkinson MC, Evans KT, Peeling WB. Assessment of volume measurement of the prostate using per-rectal ultrasonography. Br J Urol 1989; 64: 493-5.
    Pubmed CrossRef
  16. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71.
    CrossRef
  17. Garraway WM, Russell EB, Lee RJ, Collins GN, McKelvie GB, Hehir M, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43: 31821.
  18. Baik I, Shin C. Prospective study of alcohol consumption and metabolic syndrome. Am J Clin Nutr 2008; 87: 1455-63.
    Pubmed CrossRef
  19. World Health Organization. Western Pacific Region. International Association for the Study of Obesity. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia PtyLimited;2000.
  20. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 495-507.
    Pubmed
  21. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9.
    CrossRef
  22. Boyle P, McGinn R, Maisonneuve P, La Vecchia C. Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed. Eur Urol 1991; 20 Suppl 1: 3-10.
    Pubmed CrossRef
  23. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 461-75.
    Pubmed
  24. Lee S, Min HG, Choi SH, Kim YJ, Oh SW, Kim YJ, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring) 2006; 14: 172-9.
    Pubmed CrossRef
  25. Jung JH, Ahn SV, Song JM, Chang SJ, Kim KJ, Kwon SW, et al. Obesity as a risk factor for prostatic enlargement: a retrospective cohort study in Korea. Int Neurourol J 2016; 20: 321-8.
    Pubmed KoreaMed CrossRef
  26. Sidney S, Quesenberry C Jr, Sadler MC, Lydick EG, Guess HA, Cattolica EV. Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology 1991; 38(1 Suppl): 13-9.
    CrossRef
  27. Platz EA, Rimm EB, Kawachi I, Colditz GA, Stampfer MJ, Willett WC, et al. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. Am J Epidemiol 1999; 149: 106-15.
    Pubmed CrossRef
  28. Guess HA. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 1992; 14: 131-53.
    Pubmed CrossRef
  29. Suzuki S, Platz EA, Kawachi I, Willett WC, Giovannucci E. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr 2002; 75: 689-97.
    Pubmed CrossRef
  30. Platz EA, Kawachi I, Rimm EB, Colditz GA, Stampfer MJ, Willett WC, et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med 1998;158: 2349-56.
    Pubmed CrossRef


This Article


Author ORCID Information

Services
Social Network Service

e-submission

Archives